PropertyValue
?:abstract
  • Coronavirus disease (COVID-19) is caused by SARS-CoV-2 virus, which can result in serious respiratory illnesses such as pneumonia leading to respiratory failure. It was first reported in Wuhan, Hubei, China, in December 2019 and rapidly spread globally, becoming a pandemic in March 2020. Among comorbidities observed in SARS-CoV-2 positive patients, hypertension (68.3%) and type 2-diabetes (30.1%) are the most frequent conditions. Although symptoms are highly heterogeneous (ranging from absence of symptoms to severe acute respiratory failure), patients with metabolic-associated diseases often experience worse COVID-19 outcomes. This review investigates the association between metabolic disorders and COVID-19 severity, exploring the molecular mechanisms potentially underlying this relationship and those that are responsible for more severe COVID-19 outcomes. In addition, the role of the main biological processes that may connect metabolic alterations to SARS-CoV-2 infection such as hyperglycemia, immune system deregulation, ACE-2 receptor modulation, and inflammatory response is described. The impact of metabolic disorders on the prognosis of COVID-19 has major implications in public health especially for countries affected by a high incidence of metabolic diseases.
is ?:annotates of
?:creator
?:doi
?:doi
  • 10.1155/2020/8896536
?:journal
  • Int_J_Endocrinol
?:license
  • cc-by
?:pdf_json_files
  • document_parses/pdf_json/f0ab078361ae8ff267bb9280f9123af65f5d9ed2.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7703458.xml.json
?:pmcid
?:pmid
?:pmid
  • 33312199.0
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:sha_id
?:source
  • Medline; PMC
?:title
  • Metabolic Perturbations and Severe COVID-19 Disease: Implication of Molecular Pathways
?:type
?:year
  • 2020-11-28

Metadata

Anon_0  
expand all